Kellen L. Meadows

1.2k total citations
29 papers, 973 citations indexed

About

Kellen L. Meadows is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Kellen L. Meadows has authored 29 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Genetics. Recurrent topics in Kellen L. Meadows's work include Genetics and Neurodevelopmental Disorders (9 papers), Autism Spectrum Disorder Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). Kellen L. Meadows is often cited by papers focused on Genetics and Neurodevelopmental Disorders (9 papers), Autism Spectrum Disorder Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). Kellen L. Meadows collaborates with scholars based in United States, United Kingdom and Norway. Kellen L. Meadows's co-authors include Herbert I. Hurwitz, Stephanie L. Sherman, James L. Newman, Arne Klungland, Paul W. Doetsch, Tina T. Saxowsky, Dana C. Crawford, Lisa F. Taft, Patricia Holmgreen and Marshalyn Yeargin‐Allsopp and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Kellen L. Meadows

29 papers receiving 956 citations

Peers

Countries citing papers authored by Kellen L. Meadows

Since Specialization

Citations

This map shows the geographic impact of Kellen L. Meadows's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kellen L. Meadows with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kellen L. Meadows more than expected).

Fields of papers citing papers by Kellen L. Meadows

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kellen L. Meadows. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kellen L. Meadows. The network helps show where Kellen L. Meadows may publish in the future.

Co-authorship network of co-authors of Kellen L. Meadows

This figure shows the co-authorship network connecting the top 25 collaborators of Kellen L. Meadows. A scholar is included among the top collaborators of Kellen L. Meadows based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kellen L. Meadows. Kellen L. Meadows is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I study of pazopanib plus TH-302 in advanced solid tumors 2017 ·Cancer Chemotherapy and Pharmacology ·Richard F. Riedel, Kellen L. Meadows, (unknown), Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, Donna Niedzwiecki, Christel Rushing, (unknown), Herbert I. Hurwitz	9
2	Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study 2014 ·Supportive Care in Cancer ·Kellen L. Meadows, Christel Rushing, Wanda Honeycutt, (unknown), (unknown), (unknown), Donna Niedzwiecki, Herbert I. Hurwitz	17
3	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer 2013 ·Investigational New Drugs ·John H. Strickler, Shannon J. McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Lee Cohn, Alexander Starodub, (unknown), (unknown), Kellen L. Meadows, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Shiaowen David Hsu, S. Yousuf Zafar, Herbert I. Hurwitz	18
4	A phase I study ofABT‐510 plus bevacizumab in advanced solid tumors 2013 ·Cancer Medicine ·Hope E. Uronis, (unknown), Johanna C. Bendell, Gerard C. Blobe, Michael A. Morse, Andrew B. Nixon, Andrew Dellinger, Mark D. Starr, Haiyan Li, Kellen L. Meadows, Jon P. Gockerman, Herbert Pang, Herbert I. Hurwitz	21
5	Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·John H. Strickler, Alexander Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, Hope E. Uronis, P. Kelly Marcom, S. Yousuf Zafar, (unknown), Herbert I. Hurwitz	36
6	Anti-VEGF Therapies in the Clinic 2012 ·Cold Spring Harbor Perspectives in Medicine ·Kellen L. Meadows, Herbert I. Hurwitz	187
7	A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Gordana Vlahovic, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S. Yousuf Zafar, A. Alvarez-Secord, Jon P. Gockerman, Alexander Starodub, Neal Ready, Élizabeth Anderson, Johanna C. Bendell, Herbert I. Hurwitz	33
8	A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer 2011 ·Cancer Investigation ·Nan Soon Wong, Kellen L. Meadows, Lee S. Rosen, Alex A. Adjei, Scott H. Kaufmann, Michael A. Morse, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Michael L. Meyers, Herbert I. Hurwitz	10
9	Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array 2011 ·Experimental and Molecular Pathology ·Kellen L. Meadows, (unknown), Zongli Xu, Gleta Carswell, Shannon K. Laughlin, Donna D. Baird, Jack A. Taylor	4
10	A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) 2010 ·Cancer Chemotherapy and Pharmacology ·Karen Bullock, William P. Petros, Islam R. Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S. Yousuf Zafar, Jon P. Gockerman, Joanne Lager, (unknown), Kellen L. Meadows, (unknown), (unknown), Gloria Broadwater, Herbert I. Hurwitz, Johanna C. Bendell	25
11	Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors 2010 ·Cancer Chemotherapy and Pharmacology ·Carlos A. Castañeda, Kellen L. Meadows, (unknown), Michael A. Morse, Scott H. Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Herbert I. Hurwitz	17
12	Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. 2009 ·PubMed ·Elizabeth M. Dugan, (unknown), Kellen L. Meadows, Gerard C. Blobe, Michael Morse, Nishan H. Fernando, Jon P. Gockerman, William P. Petros, Herbert I. Hurwitz	3
13	Dynamic Compartmentalization of Base Excision Repair Proteins in Response to Nuclear and Mitochondrial Oxidative Stress 2008 ·Molecular and Cellular Biology ·Lyra Griffiths, Dan Swartzlander, Kellen L. Meadows, Keith D. Wilkinson, Anita H. Corbett, Paul W. Doetsch	37
14	Characterization of AP lyase activities of Saccharomyces cerevisiae Ntg1p and Ntg2p: implications for biological function 2003 ·Nucleic Acids Research ·Kellen L. Meadows	34
15	Prevalence of the fragile X syndrome in African‐Americans 2002 ·American Journal of Medical Genetics ·Dana C. Crawford, Kellen L. Meadows, James L. Newman, Lisa F. Taft, Elizabeth Scott, Mary Leslie, (unknown), Patricia Holmgreen, Marshalyn Yeargin‐Allsopp, Coleen Boyle, Stephanie L. Sherman	113
16	Survey of the Fragile X Syndrome CGG Repeat and the Short-Tandem-Repeat and Single-Nucleotide-Polymorphism Haplotypes in an African American Population 2000 ·The American Journal of Human Genetics ·Dana C. Crawford, Charles E. Schwartz, Kellen L. Meadows, James L. Newman, Lisa F. Taft, Chris Gunter, (unknown), Nancy J. Carpenter, Patricia N. Howard‐Peebles, Kristin G. Monaghan, Sarah L. Nolin, Allan L. Reiss, Gerald L. Feldman, Elizabeth M. Rohlfs, Stephen T. Warren, (unknown)	44
17	Prevalence and Phenotype Consequence of FRAXA and FRAXE Alleles in a Large, Ethnically Diverse, Special Education–Needs Population 1999 ·The American Journal of Human Genetics ·Dana C. Crawford, Kellen L. Meadows, James L. Newman, Lisa F. Taft, Dorothy Pettay, (unknown), S. J. Hersey, (unknown), (unknown), Patricia Holmgreen, Marshalyn Yeargin‐Allsopp, (unknown), (unknown)	99
18	Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population 1996 ·American Journal of Medical Genetics ·Kellen L. Meadows, Dorothy Pettay, James L. Newman, (unknown), Allison E. Ashley‐Koch, Stephanie L. Sherman	3
19	Examination of factors that influence the expansion of the fragile X mutation in a sample of conceptuses from known carrier females 1996 ·American Journal of Medical Genetics ·Stephanie L. Sherman, Kellen L. Meadows, Allison E. Ashley‐Koch	27
20	Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population 1996 ·American Journal of Medical Genetics ·Kellen L. Meadows, Dorothy Pettay, James L. Newman, (unknown), Allison E. Ashley‐Koch, Stephanie L. Sherman	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact